Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by susceptibility to bacterial and fungal infections resulting from the inadequacy of phagocytic leucocytes to produce reactive oxygen radicals. CGD is a genetically heterogeneous disease with an X-linked recessive (XR-CGD) form caused by mutations in the CYBB (OMIM #300481) gene encoding the gp91 (phox) protein, and an autosomal recessive (AR-CGD) form caused by mutations in the CYBA (OMIM #608508), NCF1 (OMIM #608512), NCF2 (OMIM #608515) and NCF4 (OMIM #601488) genes encoding p22(phox), p47(phox), p67(phox) and p40(phox), respectively. The genetic mutation of one of the cytosolic p47phox/p67phox proteins and membrane-bound gp91phox/p22phox proteins, which constitutes the NADPH oxidase enzyme complex, causes the disease. In this study, we evaluated the clinical, laboratory and genetic findings and the prognostic effects of molecular inheritance of our 24 CGD cases (14 XR, 10 autosomal recessive-AR). Consanguinity (three XR and all AR cases) showed statistically significant relationship with the type of hereditary inheritance (P < 0.001). 83% patients had an infection since early infancy. The mean age of initiation of symptoms was earlier in XR cases, and 78% patients had respiratory tract infections. Bone marrow transplantation was performed in five XR cases (two ex) and four AR (one ex) cases. Three of nine XR and two of six AR cases deceased on medical follow-up. In countries especially with high consanguinity rates, the early diagnosis for appropriate prophylactic treatment of CGD is quietly important to avoid from recurrent severe infections, early death and fatal complications of late transplantation.
| INTRODUCTION
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by susceptibility to bacterial and fungal infections resulting from the inadequacy of phagocytic leucocytes' reactive oxygen radical production. [1] [2] [3] The disease occurs approximately between 1:200 000 and 1:250 000 live births and may present at any age from infancy to late adulthood; however, the vast majority of patients are diagnosed at <5 years of age. 4 In normal phagocytic leucocytes, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex produce reactive oxygen radicals for the killing of bacteria and fungi (respiratory burst). Any defect in one of the five subunits of this enzyme (membrane-bound gp91phox/p22phox and cytosolic p47phox/p67phox/p40phox proteins) and a mutation in genes encoding these proteins is responsible for the disease. [5] [6] [7] Patients with a less severe mutation have greater residual reactive oxygen radical production and less severe disease. 8, 9 The transmembrane glycoprotein gp91phox is encoded by CYBB gene on the X chromosome and mutations in the gp91phox gene which are responsible for 65% of the cases show X-related (XR) inheritance. Autosomal recessive (AR) mutations in NCF1 (p47phox) gene account for about 25% of cases, and mutations in CYBA (p22phox) and NCF2 (p67phox) genes each account for about 5% of cases. 3, 7 There has been also one reported case of an NCF4 (p40phox) mutation resulting in CGD. 10 The CGD incidence varies significantly worldwide, from 1:1 million in Italy to 1:70 000 in the Israeli Arab population. In countries with high rates of consanguinity, the rate of AR-CGD exceeds that of XR-CGD. 3, [11] [12] [13] In approximately two-thirds of patients, the first symptoms of CGD appear during the first year of life in the form of infections, dermatitis, gastrointestinal complications and failure to thrive. Patients are in risk of life-threatening infections with catalase-positive bacteria and fungi which consume cytoplasmic hydrogen peroxide and survive intracellularly. Pneumonia is the most common type of infection encountered in CGD in all age groups and is typically caused by Staphylococcus aureus (S aureus), Aspergillus species and enteric gram negative bacteria. Cutaneous abscesses, lymphadenitis, recurrent impetigo, hepatic abscesses and perirectal abscesses are also common in CGD patients.
14 Inflammatory manifestations causing granulomas are also common in patients with CGD and are noted most frequently in the gastrointestinal tract, urogenital tract, lungs and eyes. 8, 15 X-linked recessive-CGD patients tend to present earlier and have more severe disease, develop failure to thrive, severe bacterial adenitis, abscesses or osteomyelitis within the first year of life and have earlier age of death. 16 They develop inflammatory disease twofold frequent than those with AR disease. 17 Improved awareness of the CGD disease and advances in management have led to a marked improvement in life expectancy in CGD. The prophylactic treatments have contributed to the increase in survival rates over time. 8 Allogeneic hematopoietic stem cell transplantation (HSCT), which is the definitive treatment for CGD should be performed as soon as possible in severely affected patients, to prevent irreversible tissue damage. 18 In our country, because of high consanguinity rates (25%), we should be aware of early signs of the disease and we must take the necessary precautions as early as possible. It is now possible to confirm diagnosis CGD in a short time by targeted next-generation sequencing or whole genome sequence analysis. In this study, we evaluated the clinical, laboratory and genetic findings of our CGD cases from past (1990s) to present and we aimed to identify common findings in our population as well as the prognostic effects of molecular pathologies.
| PATIENTS AND METHODS
Twenty-four CGD patients who were followed in Clinics of Pediatric Immunology, Ege University, Turkey were retrospectively evaluated for family history, consanguinity, clinical and laboratory findings, molecular examinations, treatment and prognosis. The study was approved by the ethics committee, and no financial support was received. The written informed consent was obtained from parents.
The guiding principles of ESID (European Society of Immunodeficiencies) diagnosis criteria of CGD have been used, and the diagnosis was mainly confirmed by quantification of the patients' neutrophil oxidative burst. Patients with one of the following findings: (a) severe infection (liver, perirectal or lung abscess; adenitis; or osteomyelitis) due to staphylococcus, serratia marcescens, candida or aspergillus (b) diffuse granulomata in respiratory, gastrointestinal or urogenital tracts (c) failure to thrive and hepatosplenomegaly or lymphadenopathy, were diagnosed as probable CGD. For the definitive diagnosis of CGD during the clinical follow-up and appropriate treatment approach, cases with abnormal respiratory burst testing were evaluated for any mutation in the gp91, p22, p47, p67 and p40 phox genes.
In order to quantify the oxidative burst activity, "Phagoburst test" kit (Glycotope Biotechnology GmbH, Heidelberg, Germany) for heparinized whole blood specimens was used. This test determines the percentage of phagocytic cells, which produce reactive oxidants in the presence of stimulants as unlabeled opsonized bacteria Escherichia coli (E coli), the chemotactic peptide fMLP (nformyl-methionine-leucine-phenylalanine), and PMA (phorbol-12-myristate-13-acetate) (conversion of the fluorogenic substrate dihydrorhodamine [DHR] 123 to rhodamine [R] 123) and also cells' enzymatic activity (amount of R 123 per cell). Normal reference values are as follows: for granulocytes by stimulant E. Coli: 95%-100%, fMLP: 1%-20% and PMA: 99%-100%. The evaluation of oxidative burst ( Figure 1 ) and lymphocyte subpopulations were made by FacsCalibur flow cytometry (BD Biosciences). Immunophenotyping of peripheral blood lymphocytes was performed for some patients to exclude other primary immunodeficiency disorders. SPSS 16 .0 program was used for statistical analysis (SPSS Inc., Chicago, IL, USA). One sample Kolmogorov-Smirnov test was used to check the Gaussian distribution of all variables. Both chi-square and Fisher exact tests were used to compare differences in percentages for categorical variables and Mann-Whitney U test for nonparametric conditions was used to compare means for continuous variables. All data were expressed as mean plus or minus SD except when indicated otherwise. Months of survival were described by Kaplan-Meier estimates. Differences between groups were considered significant at P < 0.05 value.
| Genetic analysis

| RESULTS
Chronic granulomatous disease patients (six girls, 18 boys) with a mean age 129.5 ± 85.7 months (19-282) were evaluated retrospectively. Patients were suspected on clinical findings and the diagnosis was confirmed by functional, molecular and genetic studies. The mean ages at initiation of symptoms, at admission and at diagnosis were 13.7 ± 20.5 (1-72), 32.7 ± 35.1 (6-108) and 57.5 ± 53.8 months, consecutively. Mainly, the mean delay in diagnosis was 45.9 ± 54.1 (1-188) months. Thirteen patients (54%) were born from consangineous parents, and eight patients (33%) had a family history for primary immunodeficiency.
A total of 37.5% (n = 9) patients had failure to thrive, and 83% (n = 20) patients had an infection since early infancy. Fifteen patients (62%) suffered from recurrent respiratory tract infections and the other frequent clinical findings were as follows: organomegaly (37%, n = 9), lymphadenopathy (45%, n = 11), dermatitis (29%, n = 7), recurrent abscess (58%, n = 14), hepatic abscess (16%, n = 4), perianal abscess (37%, n = 9), skin abscess (45%, n = 11), atalectasis (41%, n = 10) and bronchiectasis (29%, n = 7). 
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Patients suffered from fungal (25%, n = 6) and mycobacterial (50%, n = 12) infections. Nine patients with pulmonary (37%) and one patient (4%) with disseminated tuberculosis were detected. Aspergillosis was seen in three (12%) patients, and there was bronchiectasis in one of them who is still under medical follow-up. Staphylococcus aureus, Mycobacterium tuberculosis, Enterobacter spp. and Candida spp. were the other microorganisms that were isolated. Vaccination with Bacille Calmette-Gue´rin (BCG) resulted in subsequent localized skin infection in six patients (BCG-itis) and we detected one patient with BCGosis.
In molecular examination, fourteen patients had XR and ten patients (four boys, six girls) showed AR inheritance. Table 1 summarizes the demographic data of XR and AR-CGD patients. Consanguinity was seen in three XR and all AR-CGD cases and showed statistically significant relationship with the type of hereditary inheritance (P < 0.001). The mean age of initiation of symptoms was earlier in XR cases and was statistically different between both XR (9.46 ± 18.9 months) and AR (22.4 ± 21.4 months) groups (P = 0.003). Nor age at admission (P = 0.233) neither age at diagnosis (P = 0.659) showed statistically significant difference. Six XR-CGD patients had novel mutation.
The frequencies of clinical findings and the relationship with the type of hereditary transmission are summarized in Table 2 . XR inherited patients had organomegaly more frequent than AR patients (P = 0.011). Figures 2 and 3 also show cases in which the deep tissue defect is observed. Epilepsy, portal vein thrombosis and hemophagocytic lymphohistiocytosis were the ongoing diseases in three XR-CGD patients.
The respiratory burst response was low in all patients. The mean percentage of phagocytic cells was 17.9 ± 12.9 for stimulant PMA and was 29.4 ± 27.4 for E. coli. There was no significant relationship between the type of hereditary transmission and mild/severe clinical course of the disease (P = 0.779). Table 3 summarizes the molecular defects, type of inheritance, treatments and final status for all patients individually. Bone marrow transplantation (BMT) was performed in five XR cases (two ex, three cured) and four AR cases (one ex, two cured, one chronic GVD). The mean transplantation age was lower in XR patients (65.6 ± 22.6 months) than AR (99.5 ± 45.7 months) patients (P = 0.325) and the mean time between the diagnosis and BMT was also lower in XR patients (40.2 ± 14.4 months) than AR patients (53.7 ± 32.3 months), consecutively (P = 0.539). Three of nine XR cases, two of six AR cases deceased during medical follow-up (Table 3) . 
| DISCUSSION
Chronic granulomatous disease is a rare primary immunodeficiency that can manifest itself in a variety of clinical status in different genetic, ethnic etc populations.The disease is diagnosed in most children in the first 1-3 years of life and the estimated incidence is 1 in~200 000 live births. 9 To date, apart from the description of several smaller cohorts, [11] [12] [13] 22 The clinical course of CGD depends on various conditions. As the type of mutation is responsible for the diversity of symptoms, the residual NADPH oxidase activity is also associated with subsequent disease-related complications. Recurrent infections are caused by a subset of catalase-positive microorganisms, and the most common sites of infections are the lungs, skin, lymph nodes and liver and most patients have recurrent pneumonia, skin abscesses, deep organ abscesses. 11, 16, 22 In our group, 62% patients suffered from recurrent respiratory tract infections and 58% of the patients had recurrent abscess. The most frequent pathogens are Aspergillus, S. Burkholderia, Serratia, Nocardia and Salmonella. 4, 16, 22, 26, 27 We isolated S aureus, M tuberculosis, Enterobacter spp., Candida spp. in some patients. Chronic granulomatous disease has the highest prevalence of invasive fungal infections among all primary immunodeficiencies, affecting 20%-40% of CGD patients, and invasive fungal infections remain an important contributor to morbidity and mortality. 28, 29 Aspergillus species constitutes a major pathogen, being responsible for onethird of all deaths. 29 A total of 25% patients suffered from fungal infections in our group and aspergillosis was seen in three patients (one XR, two AR). Two of them had also bronchiectasis and one of them (AR) is still alive and under medical follow-up. In addition to recurrent and severe infections, dysregulated inflammation is commonly seen in CGD patients. Manifestations of autoimmunity or autoinflammation have been claimed to be more prevalent in CGD patients than in the normal population. Bortelotto et al 27 reported that 37%
and Marciano et al 30 reported that 33% of the CGD patients had colitis. There were only two patients (one XR, one AR patient) with gastrointestinal involvement in our group (Table 2) . XR-CGD patients had two times the rate of inflammatory complications compared to AR-CGD patients.
F I G U R E 2 A sectional computed tomography image of left lung
in an AR-CGD patient which revealed abscess in lower lobe adjacent to the apex of the heart and parenchymal chronic consolidation with punctate calcification in upper lobe (Table 3 , case no = 13) F I G U R E 3 A sectional computed tomography image of liver in a XR-CGD patient with multilocular abscess image over the medial contour of the right lower lobe (Table 3 , case no = 15)
In developing countries, also in our country, Mycobacterium bovis and M tuberculosis are important pathogens 31, 32 and national vaccination programs are implemented. Following vaccination with BCG (attenuated mycobacterial bovis), CGD patients may develop adverse reactions, such as BCG-itis, usually a local inflammation, although sometimes developing into disseminated tuberculosis. Vaccination with BCG resulted in BCG-itis in our six patients (five XR, one AR) and we detected one patient with BCGosis. Nine patients with pulmonary and one patient with disseminated tuberculosis were detected.
Reports from Europe, 4 the United States, 16 and Japan 24 showed that XR-CGD is the most common form of the disease (60%) compared to AR-CGD (40%). In contrast Iranian, 12 and Turkish, 13 Omani 33 cohorts reported AR as the predominant form of CGD due to the high frequency of consanguineous marriages. 34 Fourteen of our patients showed XR and 10 showed AR inheritance (Table 1) . Although consanguinity rate was high in our whole group, (n = 13, 54%) we could not identify AR inheritance dominance. But, the presence of consanguinity statistically related to the type of hereditary inheritance. It should be kept in mind that flow cytometric analysis offers a rapid and sensitive option when the facilities for the genetic diagnosis are not available (34) . The mean age of initiation of symptoms were earlier in our XR cases as compatible to other reports 3, 4, 16 and was statistically different between both groups. On the other hand, mean diagnosis age showed no statistically significant difference between two groups but, was earlier in AR group (Table 1 ) which was about 8.8 years in European study 4 and was 7.81 years in the United States Study. 16 These values probably vary with regard to the fact that awareness differs among societies. Despite the high frequency of clinical findings in the groups, generally, there was no significant relationship to type of hereditary transmission (Table 2) . Organomegaly in XR-CGD patients was more frequent than AR patients, and the deep tissue defects were observed in both groups (Figures 2 and 3) , but there was no significant relationship 35 We detected that six of our XR-CGD patients had novel mutation ( Table 3) . As far as the clinical course of the disease, environmental factors such as socio-economic conditions, and medical service possibilities are determining factors in treatment, prognosis and outcome. The prolonged tissue damage and the secondary complications as extensive fibrosis, granuloma formation and pulmonary bronchiectasis, seem to be a determining factor in patient mortality. 24, 26 In our group, three XR and two AR-CGD cases deceased on medical follow-up ( Table 3) . The definitive indications, optimum time for transplantation may be controversial, but there is a consensus that patients with poor prognosis and life-threatening infections are definite candidates for early transplantation. 36 For patients without an HLA-compatible donor, gene therapy which has not yet used in our country as a choice would be a good alternative to transplantation. During clinical follow-up, BMT was performed in five XR (three cured) and four AR cases (one cured and one had chronic GVD) in our group. XR patients had lower mean transplantation age than AR-CGD patients and the mean time between the diagnosis and BMT was also shorter. In studies published since 2000, mortality has been generally shown to be higher for patients with the XR form than those with the AR form 4, 16 with one recent study reporting a median survival of almost 50% 25 years after diagnosis. 37 Four XR and four AR patients were deceased among three decads. Overall cumulative survival of our CGD patients was about 9.38 years after admission. It was about 10.2 years in XR and 6.8 years in AR-CGD patients (log rank statistics; P = 0.567). Our data may be different from Middle East countries with high consanguinity rates as because we provide higher awareness for primary immunodeficiencies in the west of the country. Our patient population was not big enough to make a generalize approach to disease and both XR and AR-CGD groups were close in terms of number of patients. However, given the high rates of consanguinity in general Turkish population, a comprehensive national registry system is needed to determine the incidence, prevalance and also clinical, laboratory, molecular data, treatment modalities and prognosis of CGD. The early diagnosis and the initiation of appropriate prophylactic treatment and as soon as possible donor screening for haemopoietic stem cell transplantation are crucial to avoid recurrent infections and premature death.
